Day One Reports Second Quarter 2025 Financial Results and Corporate Progress
Provided By GlobeNewswire
Last update: Aug 5, 2025
OJEMDA™ (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase
OJEMDA full-year 2025 net product revenue expected to be $140 to $150 million
Read more at globenewswire.com
